• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

接受blinatumomab 治疗后复发/难治性 B 细胞前体急性淋巴细胞白血病患儿白血病细胞免疫表型的变化。

Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, who have been treated with Blinatumomab.

机构信息

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology; 1 Samory Mashela St., Moscow 117998, Russian Federation.

出版信息

Haematologica. 2021 Jul 1;106(7):2009-2012. doi: 10.3324/haematol.2019.241596.

DOI:10.3324/haematol.2019.241596
PMID:33375769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8252946/
Abstract

Not available.

摘要

无法提供。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb16/8252946/6e36c2048f4d/1062009.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb16/8252946/8d04a35d15a5/1062009.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb16/8252946/3cd0340d7b1c/1062009.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb16/8252946/6e36c2048f4d/1062009.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb16/8252946/8d04a35d15a5/1062009.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb16/8252946/3cd0340d7b1c/1062009.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb16/8252946/6e36c2048f4d/1062009.fig3.jpg

相似文献

1
Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, who have been treated with Blinatumomab.接受blinatumomab 治疗后复发/难治性 B 细胞前体急性淋巴细胞白血病患儿白血病细胞免疫表型的变化。
Haematologica. 2021 Jul 1;106(7):2009-2012. doi: 10.3324/haematol.2019.241596.
2
Different sensitivity of CD19-positive bone marrow and lymph node lymphoblasts may cause resistance to blinatumomab in relapsed B-cell acute lymphoblastic leukemia/lymphoma.CD19阳性的骨髓和淋巴结淋巴母细胞的不同敏感性可能导致复发的B细胞急性淋巴细胞白血病/淋巴瘤对blinatumomab产生耐药性。
Leuk Lymphoma. 2020 May;61(5):1230-1233. doi: 10.1080/10428194.2019.1706737. Epub 2020 Jan 3.
3
Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.blinatumomab 治疗急性淋巴细胞白血病：首个获得 EMA 批准用于微小残留病的双特异性 T 细胞衔接抗体
Oncologist. 2020 Apr;25(4):e709-e715. doi: 10.1634/theoncologist.2019-0559. Epub 2019 Nov 14.
4
Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.在blinatumomab 治疗后复发的急性淋巴细胞白血病中，骨髓和髓外部位之间出现骨髓外复发和 CD19 表达不一致。
Curr Probl Cancer. 2019 Jun;43(3):222-227. doi: 10.1016/j.currproblcancer.2018.04.006. Epub 2018 May 7.
5
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.在复发/难治性Ph阴性B细胞前体急性淋巴细胞白血病儿童患者中，博纳吐单抗与历史标准疗法的对比研究
Leukemia. 2020 Sep;34(9):2473-2478. doi: 10.1038/s41375-020-0770-8. Epub 2020 Feb 24.
6
Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.复发/难治性B前体急性淋巴细胞白血病患者复发后使用博纳吐单抗进行再治疗。
Leukemia. 2018 Feb;32(2):562-565. doi: 10.1038/leu.2017.306. Epub 2017 Oct 9.
7
Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia.博纳吐单抗可改善复发的B细胞急性淋巴细胞白血病患儿的预后。
Clin Transl Oncol. 2021 Sep;23(9):1963-1966. doi: 10.1007/s12094-021-02590-0. Epub 2021 Mar 19.
8
Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.博纳吐单抗：用于前体B细胞急性淋巴细胞白血病的首款双特异性T细胞衔接器。
Ann Pharmacother. 2015 Sep;49(9):1057-67. doi: 10.1177/1060028015588555. Epub 2015 Jun 3.
9
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Blinatumomab 治疗成人复发/难治性 B 前体急性淋巴细胞白血病患者的安全性和疗效：一项多中心、单臂、2 期研究。
Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.
10
Delayed-onset severe neurotoxicity related to blinatumomab in an adolescent patient with refractory acute lymphoblastic leukemia.一名患有难治性急性淋巴细胞白血病的青少年患者中与博纳吐单抗相关的迟发性严重神经毒性。
Pediatr Blood Cancer. 2021 Jul;68(7):e29040. doi: 10.1002/pbc.29040. Epub 2021 Mar 31.

引用本文的文献

1
Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy.用于监测B细胞前体急性淋巴细胞白血病患者CD19靶向治疗后微小残留病的可靠流式细胞术方法
Cancers (Basel). 2022 Nov 5;14(21):5445. doi: 10.3390/cancers14215445.
2
Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives.儿童急性淋巴细胞白血病的免疫治疗：最新进展和未来展望。
Front Immunol. 2022 Jun 13;13:921894. doi: 10.3389/fimmu.2022.921894. eCollection 2022.
3
Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy.

本文引用的文献

1
Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies.T细胞靶向治疗后B淋巴细胞白血病残留疾病的流式细胞术监测
Curr Protoc Cytom. 2018 Oct;86(1):e44. doi: 10.1002/cpcy.44. Epub 2018 Sep 13.
2
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment.接受blinatumomab治疗后小儿B细胞前体急性淋巴细胞白血病的CD19阴性复发
Blood Cancer J. 2017 Dec 20;7(12):659. doi: 10.1038/s41408-017-0023-x.
3
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression.
在博纳吐单抗治疗下小儿B细胞前体急性淋巴细胞白血病中的谱系转换
Int J Mol Sci. 2022 Apr 5;23(7):4019. doi: 10.3390/ijms23074019.
4
Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?造血细胞移植后，能否将针对B细胞急性淋巴细胞白血病的移植物抗白血病（GVL）效应与移植物抗宿主病（GVHD）分开？
Front Pediatr. 2022 Mar 24;10:796994. doi: 10.3389/fped.2022.796994. eCollection 2022.
5
Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells.复发/难治性B细胞前体急性淋巴细胞白血病患儿经表达CD19导向嵌合抗原受体（CAR）的T细胞治疗后白血病原始细胞的免疫表型变化
Haematologica. 2022 Apr 1;107(4):970-974. doi: 10.3324/haematol.2021.279677.
6
Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review).博纳吐单抗用于儿童急性淋巴细胞白血病——从挽救治疗到一线治疗（系统评价）
J Clin Med. 2021 Jun 8;10(12):2544. doi: 10.3390/jcm10122544.
blinatumomab 治疗失败后复发/难治性急性淋巴细胞白血病患者的结局：CD19 表达水平无变化。
Am J Hematol. 2018 Mar;93(3):371-374. doi: 10.1002/ajh.24987. Epub 2017 Dec 23.
4
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.博纳吐单抗对比化疗治疗晚期急性淋巴细胞白血病
N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.
5
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.Blinatumomab 治疗儿童复发/难治性急性淋巴细胞白血病的 I/II 期研究。
J Clin Oncol. 2016 Dec 20;34(36):4381-4389. doi: 10.1200/JCO.2016.67.3301. Epub 2016 Oct 31.
6
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.复发/难治性B细胞急性淋巴细胞白血病患者中，微小残留病阴性根据挽救状态的差异影响。
Cancer. 2017 Jan 1;123(2):294-302. doi: 10.1002/cncr.30264. Epub 2016 Sep 7.
7
A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.一种新型流式细胞术检测方案，用于检测抗 CD19 治疗后 B 淋巴细胞白血病/淋巴瘤患者的残留病。
Cytometry B Clin Cytom. 2018 Jan;94(1):112-120. doi: 10.1002/cyto.b.21482. Epub 2016 Sep 23.
8
Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.采用八色流式细胞术对复发性儿童急性淋巴细胞白血病进行微小残留病分析。
Haematologica. 2015 Jul;100(7):935-44. doi: 10.3324/haematol.2014.116707. Epub 2015 May 22.
9
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.抗 CD19 双特异性 T 细胞衔接蛋白blinatumomab 的 II 期临床试验显示，复发或难治性 B 前体急性淋巴细胞白血病患者有血液学和分子缓解。
J Clin Oncol. 2014 Dec 20;32(36):4134-40. doi: 10.1200/JCO.2014.56.3247. Epub 2014 Nov 10.
10
Quality assessment program for EuroFlow protocols: summary results of four-year (2010-2013) quality assurance rounds.欧洲流式细胞术标准操作规程质量评估项目：四年（2010 - 2013年）质量保证轮次的总结结果
Cytometry A. 2015 Feb;87(2):145-56. doi: 10.1002/cyto.a.22581. Epub 2014 Oct 23.